Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)
Standard
Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO). / Nagel, Gabriele; Weber, D; Fromm, E; Erhardt, S; Lübbert, M; Fiedler, W; Kindler, T; Krauter, J; Brossart, P; Kündgen, A; Salih, H R; Westermann, J; Wulf, G; Hertenstein, B; Wattad, M; Götze, K; Kraemer, D; Heinicke, T; Girschikofsky, M; Derigs, H G; Horst, H A; Rudolph, C; Heuser, M; Göhring, G; Teleanu, V; Bullinger, L; Thol, F; Gaidzik, V I; Paschka, P; Döhner, K; Ganser, A; Döhner, Hartmut; Schlenk, R F; German-Austrian AML Study Group (AMLSG).
in: ANN HEMATOL, Jahrgang 96, Nr. 12, 12.2017, S. 1993-2003.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)
AU - Nagel, Gabriele
AU - Weber, D
AU - Fromm, E
AU - Erhardt, S
AU - Lübbert, M
AU - Fiedler, W
AU - Kindler, T
AU - Krauter, J
AU - Brossart, P
AU - Kündgen, A
AU - Salih, H R
AU - Westermann, J
AU - Wulf, G
AU - Hertenstein, B
AU - Wattad, M
AU - Götze, K
AU - Kraemer, D
AU - Heinicke, T
AU - Girschikofsky, M
AU - Derigs, H G
AU - Horst, H A
AU - Rudolph, C
AU - Heuser, M
AU - Göhring, G
AU - Teleanu, V
AU - Bullinger, L
AU - Thol, F
AU - Gaidzik, V I
AU - Paschka, P
AU - Döhner, K
AU - Ganser, A
AU - Döhner, Hartmut
AU - Schlenk, R F
AU - German-Austrian AML Study Group (AMLSG)
PY - 2017/12
Y1 - 2017/12
N2 - We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry. Adult patients with newly diagnosed AML at 63 centers in Germany and Austria were followed within the AMLSG BiO registry (NCT01252485). Between January 1, 2012, and December 31, 2014, data of 3525 patients with AML (45% women) were collected. The median age was 65 years (range 18-94). The comparison of age-specific AML incidence rates with epidemiological cancer registries revealed excellent coverage in patients < 70 years old and good coverage up to the age of 80. The distribution according to the European LeukemiaNet (ELN) risk categorization from 2010 was 20% favorable, 31% intermediate-1, 28% intermediate-2, and 21% adverse. With increasing age, the relative but not the absolute prevalence of patients with ELN favorable and intermediate-1 risk (p < 0.001), with activating FLT3 mutations (p < 0.001), with ECOG performance status < 2 (p < 0.001), and with HCT-CI comorbidity index < 3 (p < 0.001) decreased. Regarding treatment, obesity and favorable risk were associated with an intensive treatment, whereas adverse risk, higher age, and comorbidity index > 0 were associated with non-intensive treatment or best supportive care. The AMLSG BiO registry provides reliable population-based distributions of genetic, clinical, and treatment characteristics according to age.
AB - We describe genetic and clinical characteristics of acute myeloid leukemia (AML) patients according to age from an academic population-based registry. Adult patients with newly diagnosed AML at 63 centers in Germany and Austria were followed within the AMLSG BiO registry (NCT01252485). Between January 1, 2012, and December 31, 2014, data of 3525 patients with AML (45% women) were collected. The median age was 65 years (range 18-94). The comparison of age-specific AML incidence rates with epidemiological cancer registries revealed excellent coverage in patients < 70 years old and good coverage up to the age of 80. The distribution according to the European LeukemiaNet (ELN) risk categorization from 2010 was 20% favorable, 31% intermediate-1, 28% intermediate-2, and 21% adverse. With increasing age, the relative but not the absolute prevalence of patients with ELN favorable and intermediate-1 risk (p < 0.001), with activating FLT3 mutations (p < 0.001), with ECOG performance status < 2 (p < 0.001), and with HCT-CI comorbidity index < 3 (p < 0.001) decreased. Regarding treatment, obesity and favorable risk were associated with an intensive treatment, whereas adverse risk, higher age, and comorbidity index > 0 were associated with non-intensive treatment or best supportive care. The AMLSG BiO registry provides reliable population-based distributions of genetic, clinical, and treatment characteristics according to age.
KW - Adolescent
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Austria
KW - Female
KW - Germany
KW - Humans
KW - Leukemia, Myeloid, Acute
KW - Male
KW - Middle Aged
KW - Mutation
KW - Registries
KW - fms-Like Tyrosine Kinase 3
KW - Clinical Trial
KW - Journal Article
KW - Multicenter Study
U2 - 10.1007/s00277-017-3150-3
DO - 10.1007/s00277-017-3150-3
M3 - SCORING: Journal article
C2 - 29090343
VL - 96
SP - 1993
EP - 2003
JO - ANN HEMATOL
JF - ANN HEMATOL
SN - 0939-5555
IS - 12
ER -